Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Inventory For Long Term Contracts Or Programs

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryForLongTermContractsOrPrograms.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Acadia Pharmaceuticals's inventory for long term contracts or programs?
Acadia Pharmaceuticals (ACAD) reported inventory for long term contracts or programs of $80.72M in Q1 2026.
How has Acadia Pharmaceuticals's inventory for long term contracts or programs changed year-over-year?
Acadia Pharmaceuticals's inventory for long term contracts or programs increased by 0.9% year-over-year, from $80.03M to $80.72M.
What is the long-term trend for Acadia Pharmaceuticals's inventory for long term contracts or programs?
Over 4 years (2021 to 2025), Acadia Pharmaceuticals's inventory for long term contracts or programs has grown at a 87.4% compound annual growth rate (CAGR), from $6.22M to $76.7M.